

Comparison of Kvick cassettes and two competitive cassettes for the concentration and diafiltration of Human Serum Albumin (HSA)

Intellectual Property Notice: The Biopharma business of GE Healthcare was acquired by Danaher on 31 March 2020 and now operates under the Cytiva™ brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

cytiva.com

GE and the GE Monogram are trademarks of General Electric Company. Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. All other third-party trademarks are the property of their respective owners.

© 2020 Cytiva

All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.

For local office contact information, visit $\underline{\text{cytiva.com/contact}}$

Comparison of Kvick cassettes and two competitive cassettes for the concentration and diafiltration of Human Serum Albumin (HSA)

The situation

Cross flow trial filtration runs were undertaken to compare the performance of three 10 kD molecular weight cutoff cassettes, one manufactured by GE Healthcare and two from different suppliers, for the concentration and diafiltration of Human Serum Albumin (HSA).

The three primary areas of interest were as follows: (1) to determine the final concentration achieved with each type of cassette; (2) to determine the final yield from each type of cassette; and (3) to note the time required to reach that concentration. In the trial using the GE Healthcare Kvick™ cassette, a final concentration was reached of 36.9% HSA with a yield of 98.53% in ~75 minutes. Final concentrations attained using competitive cassettes were 35.9% with a yield of 95.72% in ~90 minutes.; and 36.4% with a yield of 97% in ~103 minutes.

Equipment setup for the trial run

The cross flow ultrafiltration trial runs were performed using the GE Healthcare Kvick lab system, catalog no. KLSY 0105 RLPSS20. The Kvick lab system utilizes a low shear rotary lobe pump. Three test cassettes were selected, each with a 10 kD molecular weight cutoff. One was a Kvick lab 1.2 ft² cassette, catalog no. UFELA 0010010 ST, the second a cassette from supplier X, and the third a cassette from supplier Z. The medium used for this test was pure Human Serum Albumin at 2.5% initial concentration.






Figure 1. Schematic flow diagram of the Kvick lab cross flow system used for the trial runs

Method

For each trial, the cassette undergoing the test was placed in the Kvick lab holding device, and the clamping plates tightened to the required torque.

The cassettes were prepared and an HSA solution was concentrated using the following steps:


- 1. System and cassette rinsed with deionized water (DI-water) to remove storage solution
- 2. Cassette pre-conditioned with isotonic NaCl solution
- 3. 1st concentration step, $6\times$ concentration, 3000 ml down to 500 ml
- 4. Diafiltration step, 5× 500 ml
- 5. Final concentration step, $15\times$ concentration, 3000 ml to 200 ml
- 6. Product recovery with buffer
- 7. Cleaning and storage

Results


Table 1. Shows the process parameters and comparative performance of the cassettes studied. Certain process parameters are the same for all three cassettes: the comparison medium used is HSA, 2.5% initial concentration, membrane molecular weight cutoff is 10 kD, area is 0.1 meters (Kvick cassette is 0.11), batch volume is 3.00 liters, and the diafiltration volumes are 5×500 ml.

Process condition	Kvick cassette (UFELA0010010ST)	Cassette from supplier Z	Cassette from supplier X
Temperature, 1st concentration	26°C	24°C	26°C
Temperature, diafiltration	24°C	18°C	22°C
Feed inlet pressure, 1st concentration	2.5 bar	2.5 bar	3.2 bar
Feed inlet pressure, diafiltration	2.5 bar	2.5 bar	3.2 bar
Feed inlet pressure, final concentration	2.5 bar up to 3.0 bar	2.5 bar up to 2.9 bar	3.2 bar
Retentate pressure, final concentration	1.5 bar, down to 1.2 bar	1.5 bar, down to 1.2 bar	1.2 bar, down to 0.8 bar
Permeate pressure0.0 bar	0.0 bar	0.0 bar	
Transmembrane pressure (TMP), final concentration	2.0 bar, up to 2.1 bar	2.0 bar, up to 2.2 bar	2.2 bar, up to 2.35 bar
Recirculation rate, first concentration and diafiltration	900 ml/min	820 ml/min	850 ml/min
Recirculation rate, final concentration	700 ml down to 420 ml	600 ml down to 310 ml	640 ml down to 380 ml

Comparison of HSA Final Yield



Comparison of HSA Final Concentration



Conclusions

- 1. Kvick cassettes incorporate a proprietary polyethersulfone membrane that combines a macrovoid-free structure with low protein binding characteristics.
- 2. This macrovoid-free structure, coupled with the high selectivity of the membrane, results in overall increased performance of the membrane and higher yields for the end user, as demonstrated in this trial.
- yields for the end user, as demonstrated in this trial.

3. In this comparison, the Kvick cassette demonstrated superior performance over the competition. The final yield for the HSA product was 2.81% more than supplier Z and 1.53% greater than supplier X.

www.gehealthcare.com

Global Headquarters GE Healthcare Little Chalfont Buckinghamshire, U.K. HP7 9NA GE, imagination at work and GE monogram are trademarks of General Electric Company.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. GE Healthcare reserves the right, subject to any regulatory and contractual approval, if required, to make changes in specifications and features shown herein, or discontinue the product described at any time without notice or obligation.

© 2006 General Electric Company - All rights reserved.

GE Healthcare Bio-Sciences AB, a General Electric Company.

GE Healthcare Bio-Sciences AB Björkgatan 30, 751 84 Uppsala, Sweden

GE Healthcare Europe GmbH Munzinger Strasse 5, D-79111 Freiburg, Germany

GE Healthcare UK Ltd Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK

GE Healthcare Bio-Sciences Corp 800 Centennial Avenue, P.O. Box 1327 Piscataway, NJ 08855-1327, USA

GE Healthcare Bio-Sciences KK Sanken Bldg. 3-25-1, Hyakunincho, Shinjuku-ku, Tokyo 169-0073, Japan

Asia Pacific Tel +65 6275 1830 Fax +65 6275 1829 Australasia Tel +61 2 9899 0999 Fax +61 2 9899 7511 Austria Tel 01/57606-1619 Fax 01/57606-1627 Belgium Tel 0800 73 888 Fax 02 416 82 06 Canada Tel 800 463 5800 Fax 800 567 1008 Central, East, & South East Europe Tel +43 1 972720 Fax +43 1 97272 750 Denmark Tel 45 16 2400 Fax 45 16 2424 Finland & Baltics Tel +358 (0)9 512 39 40 Fax +358 (0)9 512 39 439 France Tel 01 69 35 67 00 Fax 01 69 41 96 77 Germany Tel 089 96281 620 Fax 689 56281 620 Fax 829 56281 620 Fax 829 100 6300 Fax +852 2100 6338 Italy Tel 02 27322 1 Fax 02 27302 212 Japan Tel +81 3 5331 9335 Fax +81 935 Fax

